Production (Stage)
Aldeyra Therapeutics, Inc.
ALDX
$2.22
-$0.03-1.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -6.43% | 8.24% | 42.78% | -10.11% | -42.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.00% | 171.87% | 68.97% | 74.11% | -44.09% |
| Operating Income | -11.00% | -171.87% | -68.97% | -74.11% | 44.09% |
| Income Before Tax | -22.86% | -232.61% | -84.60% | -87.47% | 48.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.86% | -232.61% | -84.60% | -87.47% | 48.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.86% | -232.61% | -84.60% | -87.47% | 48.24% |
| EBIT | -11.00% | -171.87% | -68.97% | -74.11% | 44.09% |
| EBITDA | -11.07% | -173.80% | -69.47% | -74.60% | 44.23% |
| EPS Basic | -21.91% | -230.39% | -82.93% | -85.48% | 48.80% |
| Normalized Basic EPS | -21.88% | -230.28% | -83.04% | -85.55% | 48.80% |
| EPS Diluted | -21.91% | -230.39% | -82.93% | -85.48% | 48.80% |
| Normalized Diluted EPS | -21.88% | -230.28% | -83.04% | -85.55% | 48.80% |
| Average Basic Shares Outstanding | 0.80% | 0.65% | 0.92% | 1.06% | 1.06% |
| Average Diluted Shares Outstanding | 0.80% | 0.65% | 0.92% | 1.06% | 1.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |